(Reuters) -The U.S. Food and Drug Administration is probing the death of a patient who developed harmful antibodies after taking Takeda Pharmaceuticals' blood disorder therapy, the health regulator said on Friday.
The pediatric patient died about 10 months after starting Takeda's drug Adzynma as a preventive therapy, the agency said.
The child had congenital thrombotic thrombocytopenic purpura (cTTP), an inherited condition that causes blood clots in small vessels and can lead to organ damage.
The FDA said the child developed antibodies that blocked the activity of ADAMTS13, an enzyme critical for blood clotting.
Takeda did not immediately respond to Reuters request for comment.
Adzynma, approved in 2023 as the first therapy for cTTP, replaces the ADAMTS13 protein to help prevent dangerous blood clots.
The agency added it has received multiple postmarketing reports of patients developing neutralizing antibodies to ADAMTS13 after treatment with Adzynma.
(Reporting by Kamal Choudhury in Bengaluru; Editing by Vijay Kishore)
latest_posts
- 1
The most effective method to Explore Moral Situations in Brain research with Your Certification - 2Vial marked 'Polonium 210' sparks scare during German Easter egg hunt
- 3Common ADHD medication prescribed in childhood may protect against risk of psychosis
- 4Step by step instructions to Guarantee Your Lab Precious stone is Morally Obtained
- 5How does Spotify Wrapped calculate your listening age? What your number says about you.
- The year's first meteor shower and supermoon clash in January skies
- Most loved Specially prepared Espresso Mix: Which Meal Do You Adore the Most?
- Figure out How to Involve a Brain science Certification in Showcasing
- Figure out How to Assess the Unwavering quality of SUVs for Seniors
- Amy Poehler's podcast is a hit. It's also a Trojan horse for talking about women and aging.
- ‘This year nearly broke me as a scientist’ – US researchers reflect on how 2025’s science cuts have changed their lives
- Figure out How to Amplify Innovation and Infotainment Frameworks for Senior Drivers in SUVs
- 7 Powerful Techniques to Boost Efficiency with Your Cell Phone: A Thorough Aide
- Why doing good also makes us feel good, during the holidays and beyond
